New hope for advanced cancers? first human trial of DS5361b begins
NCT ID NCT07182591
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 192 participants will take part across multiple centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Research Site
RECRUITINGSarasota, Florida, 34232, United States
-
Research Site
RECRUITINGProvidence, Rhode Island, 02903, United States
-
Research Site
RECRUITINGIrving, Texas, 75039, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
RECRUITINGFairfax, Virginia, 22031, United States
-
Research Site
RECRUITINGKashiwa, 277-8577, Japan
-
Research Site
RECRUITINGKōtoku, 135-8550, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?